|
Princeton Docket # 12-2807
Researchers
in the Molecular Biology Department at Princeton University have discovered a
group of miRNAs as novel therapeutics for bone metastasis. Through
a series of in vitro and in vivo experiments, five distinctive miRNAs have been
identified as inhibitors of osteoclast differentiation. Further, systemic
treatment...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Brian Ell
Keywords(s): biomarker/diagnostic, Biotechnology/Pharmaceuticals, cancer/oncology, drug discovery, miRNA, therapeutic
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics
|
|
Princeton Docket #
11-2691-1
Using
various in vitro and in vivo xenograft model systems and
clinical samples, researchers in the department of molecular biology, Princeton University
have validated a stage-specific functional role of the miR-200 family to tumor
progression. Current studies
suggest that the miR-200 family may hinder an early step...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Manav Korpal
Keywords(s): biomarker/diagnostic, cancer/oncology, drug target
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics
|
|
Princeton Docket #
11-2669
Although several molecular contributors of bone metastasis have
been identified, effective therapies still await a more comprehensive
understanding of the complex molecular and cellular networks of tumor stromal
interactions in bone metastasis. Researchers in the Department of
Molecular Biology, Princeton
University...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Nilay Sethi
Keywords(s): biomarker/diagnostic, cancer/oncology, drug target, life science venture/early
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics
|
|
Princeton University Invention #
09-2551
Over 90% of cancer-related deaths are due to the metastatic spread of
primary tumor cells to distant vital organs. Epithelial-mesenchymal transition
(EMT) is a key cellular process through which tumor cells gain the ability to
migrate and invade into their surrounding tissue. The reverse process, (MET),...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Manav Korpal
Keywords(s):
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton University Invention #
09-2550
In breast cancer
patients, disseminated tumor cells from the primary site can remain in a dormant
state in the secondary organ for a long period before starting to grow into
life-threatening metastasis. However, the molecular understanding of this
process is still very limited.
Researchers in
Molecular...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Xin Lu
Keywords(s):
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton University Invention #
09-2521
Researchers in
Ecology and Evolutionary Biology and Molecular Biology, Princeton University,
have described a new process based on the natural biological
mechanism of RNA-guided DNA recombination as discovered and reported in their
recent publication, Nowacki et al. Nature 2008 January ¹.
The process...
Published: 3/15/2018
|
Inventor(s): Laura Landweber, Mariusz Nowacki, Wenwen Fang, Yibin Kang
Keywords(s):
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton University Invention #
09-2509
The involvement of the EGFR signaling pathway in bone metastasis has been
implicated by a number of studies. However, the therapeutic significance by
targeting EGFR signaling in the tumor-stroma interface has not been evaluated.
Researchers in the Molecular Biology Department at Princeton...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Xin Lu
Keywords(s): antibody, cancer/oncology, therapeutic
Category(s): Biotechnology/Pharmaceuticals
|
|
Princeton
Docket # 07-2399
Researchers
in the Molecular Biology Department at Princeton University have identified a
recurrent 8q22 genomic gain in poor-prognosis human breast cancers, which
harbors the metastasis gene Metadherin (MTDH). Genomic
gain of 8q22 elevates expression of MTDH,
which is overexpressed in more than 40% of breast cancers...
Published: 3/15/2018
|
Inventor(s): Yibin Kang, Guohong Hu
Keywords(s): Biotechnology/Pharmaceuticals, cancer/oncology, drug target, life science venture/early
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics
|
|
Princeton Invention # 07-2351
Cancer metastasis requires the
intricate interactions between cancer cells and the host tissue
microenvironment. Although TGFb signaling pathway has been
implicated in breast cancer metastasis to bone and other target organs, the
temporal-spatial requirement and the in vivo dynamics of TGFb signaling...
Published: 3/15/2018
|
Inventor(s): Yibin Kang
Keywords(s): drug discovery, life science research tools, platform technology
Category(s): Biotechnology/Pharmaceuticals
|